{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:00:23Z","timestamp":1767114023293,"version":"3.48.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.endien.2025.501654","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:20:36Z","timestamp":1765977636000},"page":"501654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Executive summary of the consensus document for the management of severe Cushing's syndrome: Consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN)"],"prefix":"10.1016","volume":"72","author":[{"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelio","family":"Garc\u00eda-Centeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Aller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Bernabeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Villar-Taibo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia A.","family":"Hanzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2025.501654_bib0300","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: a review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.endien.2025.501654_bib0305","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing's syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.endien.2025.501654_bib0310","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/17446651.2016.1123615","article-title":"Current strategies for the treatment of severe Cushing's syndrome","volume":"11","author":"Alexandraki","year":"2016","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0315","first-page":"48","article-title":"Fulminant ectopic Cushing's syndrome caused by metastatic small intestine neuroendocrine tumour \u2013 a case report and review of the literature","volume":"87","author":"Alliet","year":"2024","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.endien.2025.501654_bib0320","doi-asserted-by":"crossref","first-page":"bvaf039","DOI":"10.1210\/jendso\/bvaf039","article-title":"Etomidate in severe Cushing syndrome: a systematic review","volume":"9","author":"Muthukuda","year":"2025","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.endien.2025.501654_bib0325","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0330","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1093\/ejendo\/lvae110","article-title":"How to manage Cushing's disease after failed primary pituitary surgery","volume":"191","author":"Agrawal","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0335","article-title":"Unusual infections and thrombotic events in Cushing's syndrome","author":"Barbot","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.endien.2025.501654_bib0340","first-page":"17","article-title":"Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)","author":"van Haalen","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.endien.2025.501654_bib0345","first-page":"186","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas","author":"Tabarin","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0350","first-page":"11","article-title":"Cushing syndrome","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.endien.2025.501654_bib0355","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tem.2023.12.003","article-title":"A clinical perspective on ectopic Cushing's syndrome","volume":"35","author":"Ragnarsson","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0360","first-page":"34","article-title":"Clinical presentation and etiology of Cushing's syndrome: data from ERCUSYN","author":"Valassi","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0365","first-page":"35","article-title":"Medical therapy in severe hypercortisolism","author":"Marques","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0370","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-20-0557","article-title":"Efficacy and tolerance of osilodrostat in patients with severe Cushing's syndrome due to non-pituitary cancers","volume":"183","author":"Haissaguerre","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0375","doi-asserted-by":"crossref","first-page":"L13","DOI":"10.1530\/EJE-21-0147","article-title":"Rapid control of severe ectopic Cushing's syndrome by oral osilodrostat monotherapy","volume":"184","author":"Bessi\u00e8ne","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0380","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","article-title":"A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease","volume":"67","author":"Tanaka","year":"2020","journal-title":"Endocr J"},{"key":"10.1016\/j.endien.2025.501654_bib0385","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2147\/DDDT.S315359","article-title":"Clinical utility of osilodrostat in Cushing's disease: review of currently available literature","volume":"17","author":"Perosevic","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.endien.2025.501654_bib0390","first-page":"9","article-title":"Osilodrostat treatment for adrenal and ectopic Cushing syndrome: integration of clinical studies with case presentations","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.endien.2025.501654_bib0395","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","article-title":"Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of cushing syndrome: an in vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0400","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","article-title":"Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.endien.2025.501654_bib0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for cushing syndrome","volume":"106","author":"Tritos","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0410","first-page":"35","article-title":"Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome \u2013 a practical guide","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0415","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0420","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/ALN.0b013e3181ff72b5","article-title":"Clinical and molecular pharmacology of etomidate","volume":"114","author":"Forman","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.endien.2025.501654_bib0425","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jcem-59-6-1143","article-title":"Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation","volume":"59","author":"De Jong","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"year":"2017","author":"Newell-Price","series-title":"Cushing disease","key":"10.1016\/j.endien.2025.501654_bib0430"},{"key":"10.1016\/j.endien.2025.501654_bib0435","first-page":"3141","article-title":"Cushing syndrome","volume":"23","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.endien.2025.501654_bib0440","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing's syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2025.501654_bib0445","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0450","first-page":"13","article-title":"Ketoconazole- and metyrapone-induced reductions on urinary steroid metabolites alter the urinary free cortisol immunoassay reliability in Cushing syndrome","author":"Vega-Beyhart","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.endien.2025.501654_bib0455","first-page":"87","article-title":"Is there still a place for etomidate in the management of Cushing's syndrome? The experience of a single center of low-dose etomidate and combined etomidate-osilodrostat treatment in severe hypercortisolemia","author":"Dzialach","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.endien.2025.501654_bib0460","first-page":"2019","article-title":"A unique case of ectopic Cushing's syndrome from a thymic neuroendocrine carcinoma","author":"Lawrence","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.endien.2025.501654_bib0465","first-page":"2021","article-title":"Synergistic cortisol suppression by ketoconazole-osilodrostat combination therapy","author":"Amodru","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.endien.2025.501654_bib0470","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s42000-022-00397-4","article-title":"Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia","volume":"21","author":"Dzialach","year":"2022","journal-title":"Hormones"},{"key":"10.1016\/j.endien.2025.501654_bib0475","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12020-022-03075-y","article-title":"Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen","volume":"77","author":"Turla","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.endien.2025.501654_bib0480","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenick\u00fd","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0485","first-page":"54","article-title":"Pharmacological treatment of Cushing's syndrome","author":"Castinetti","year":"2023","journal-title":"Arch Med Res"},{"key":"10.1016\/j.endien.2025.501654_bib0490","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0495","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0500","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0505","doi-asserted-by":"crossref","first-page":"E2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0510","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0515","first-page":"12","article-title":"Cyclic Cushing's syndrome \u2013 a diagnostic challenge","author":"\u015awi\u0105tkowska-Stodulska","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.endien.2025.501654_bib0520","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","article-title":"An individualized approach to the management of Cushing disease","volume":"19","author":"Fleseriu","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0525","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11102-014-0633-2","article-title":"Bilateral adrenalectomy for Cushing's disease","volume":"18","author":"Katznelson","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.endien.2025.501654_bib0530","first-page":"105","article-title":"Outcomes of patients with Nelson's syndrome after primary treatment: a multicenter study from 13 UK pituitary centers","author":"Fountas","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0535","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/jc.2011-1661","article-title":"Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study","volume":"96","author":"Stuijver","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0540","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"Van Der Pas","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501654_bib0545","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4158\/EP161721.RA","article-title":"An individualized approach to the evaluation of Cushing syndrome","volume":"23","author":"Sharma","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.endien.2025.501654_bib0550","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11102-021-01195-8","article-title":"Venous thromboembolism chemical prophylaxis after endoscopic trans-sphenoidal pituitary surgery","volume":"25","author":"Waqar","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.endien.2025.501654_bib0555","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/ejendo\/lvaf017","article-title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement","volume":"192","author":"Isand","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0560","first-page":"2023","article-title":"Severe Cushing's syndrome from an ectopic adrenocorticotropic hormone-secreting neuroendocrine tumour treated by osilodrostat","author":"H\u00e1na","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.endien.2025.501654_bib0565","first-page":"1","article-title":"Successful management of cushing syndrome from ectopic ACTH secretion in an adolescent with osilodrostat","author":"Blew","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.endien.2025.501654_bib0570","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000527824","article-title":"Cushing's syndrome in adenocarcinoma of lung responding to osilodrostat","volume":"16","author":"Heleno","year":"2023","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.endien.2025.501654_bib0575","first-page":"15","article-title":"Case report: Thymic neuroendocrine tumor with metastasis to the breast causing ectopic Cushing's syndrome","author":"Zdrojowy-We\u0142na","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.endien.2025.501654_bib0580","first-page":"3","article-title":"Successful treatment of severe ectopic ACTH-dependent cushing syndrome complicated by hypocalcemia with osilodrostat","author":"Lee","year":"2025","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.endien.2025.501654_bib0585","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","article-title":"Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endien.2025.501654_bib0590","first-page":"9","article-title":"Osilodrostat treatment of cushing syndrome in real-world clinical practice: findings from the ILLUSTRATE study","author":"Fleseriu","year":"2025","journal-title":"J Endocr Soc"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:56:56Z","timestamp":1767113816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018025001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2530018025001416"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2025.501654","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Executive summary of the consensus document for the management of severe Cushing's syndrome: Consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN)","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2025.501654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501654"}}